English
Ton-Bridge Product
Ton-Bridge Factory Headquarters
Ton-Bridge Introduction

LATEST NEWS

Treating Multiple ICA Aneurysms with a Single Strategy: Kylin™ Flow Diverter in Practice
We are pleased to share highlights from the Ton-Bridge online session at ICR 2026 – International Congress of Radiology.
Clinical experience, device handling, and pre-market data highlighted at the SNF-ALICE meeting
A few moments from LINNC Paris 2026.
Leaders of Guangdong Provincial Drug Administration Visited Ton-Bridge Medical

Advantage

Founded in 2016 and headquartered in Zhuhai, the company has established subsidiaries and offices in Guangzhou, Hangzhou, Shanghai, and Suzhou. Following a share restructuring in 2018, it merged with Zylox Medical under the leadership of Dr. Jonathon Zhong Zhao,Chairman,and Dr. Li Zheng, General Manager.The combined entity was officially listed on the Hong Kong Stock Exchange on July 5, 2021, with the stock code: 2190.HK. The company is committed to localizing intracranial disease treatment devices and has successfully translated multiple internationally leading scientific research achievements into tangible products.

Ton-Bridge Medical

Leading level of technology platform

Ton-Bridge Medical has a mature R & D and manufacturing base, can complete the industrialization of the international leading level of technology.

Ton-Bridge Medical

Attach importance to independent research and development

Ton-Bridge Medical attaches great importance to independent research and development, and has obtained a number of patent authorization

Ton-Bridge Medical

Provide a full range of products

Ton-Bridge Medical is devoted to developing innovative neuro-interventional medical device technologies and providing a full line of solutions for ischemic stroke (AIS), intracranial aneurysm, and other neurological disorders.

Iron wire manufacturer

Founded in 2016 and headquartered in Zhuhai, the company has established subsidiaries and offices in Guangzhou, Hangzhou, Shanghai, and Suzhou. Following a share restructuring in 2018, it merged with Zylox Medical under the leadership of Dr. Jonathon Zhong Zhao,Chairman,and Dr. Li Zheng, General Manager.The combined entity was officially listed on the Hong Kong Stock Exchange on July 5, 2021, with the stock code: 2190.HK. The company is committed to localizing intracranial disease treatment devices and has successfully translated multiple internationally leading scientific research achievements into tangible products.

About Us

Founded in 2016 and headquartered in Zhuhai, the company has established subsidiaries and offices in Guangzhou, Hangzhou, Shanghai, and Suzhou. Following a share restructuring in 2018, it merged with Zylox Medical under the leadership of Dr. Jonathon Zhong Zhao,Chairman,and Dr. Li Zheng, General Manager.The combined entity was officially listed on the Hong Kong Stock Exchange on July 5, 2021, with the stock code: 2190.HK.

The company is committed to localizing intracranial disease treatment devices and has successfully translated multiple internationally leading scientific research achievements into tangible products.

read more

Latest Products

Hit enter to search or ESC to close